Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease

PURPOSE: The melanocortin receptor pan-agonist PL9643, a potential therapy for ocular diseases, was investigated in a phase 2, 12-week study in patients with dry eye disease (DED). METHODS: This was a placebo-controlled study evaluating efficacy and safety of thrice-daily PL9643. Placebo (vehicle) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, David, Kenyon, Kenneth, Ousler, George, Watson, Michael, Vollmer, Patrick, McLaurin, Eugene B., Torkildsen, Gail, Winters, Jason, Dodd, John, Jordan, Robert, Wills, Stephen T., Spana, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654643/
https://www.ncbi.nlm.nih.gov/pubmed/37677000
http://dx.doi.org/10.1089/jop.2023.0056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654643/
https://www.ncbi.nlm.nih.gov/pubmed/37677000
http://dx.doi.org/10.1089/jop.2023.0056

Ejemplares similares